TrialPath
← Back to searchRecruiting

Analysis of Human ALS Tissues and Registry of ALS Patients

NCT05067179 · University of Illinois at Chicago
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Patients will be approached during in-person or phone/online appointments and asked their consent to enter information and results from their physical examinations, electrodiagnostic testing, and other testing done as a standard of care and into a database to monitor disease progression and use them for research purposes. Also, the patients will be asked for consent to undergo a MRI scan. In a second informed consent form, patients will be enrolled to perform a rapid postmortem autopsy and have the tissue banked for research purposes. It is important to keep the consents separate because some patients may not consent to this postmortem study, but would consent to the premortem studies. The information gained from the premortem studies will be used during the postmortem examination to select tissue for further processing. Tissue from different regions, including brain, spinal cord, nerve and muscle will be processed in parallel for cellular and molecular analyses that include histology, immunostaining, in situ hybridization, protein, RNA, and small molecule analyses.
Eligibility criteria
Inclusion Criteria: * Patients over the age of 18 * Established diagnosis of ALS * Able and willing to give written informed consent and must authorize release and use of protected health information Exclusion Criteria: * Patients below the age of 18 * No diagnosis of ALS
Study design
Enrollment target: 40 participants
Age groups: adult, older_adult
Timeline
Starts: 2020-09-01
Estimated completion: 2030-01-01
Last updated: 2025-09-22
Primary outcomes
  • Imaging biomarkers (Within 6 months of participant enrollment)
  • Molecular biomarkers (Within 12 months of participant's passing)
Sponsor
University of Illinois at Chicago · other
With: Tanabe Pharma America, Inc.
Contacts & investigators
ContactAyo Fasawe · contact · afasawe@ilstu.edu · 312-413-7908
InvestigatorJeffrey Loeb, MD · principal_investigator, University of Illinois at Chicago
All locations (1)
University of Illinois at ChicagoRecruiting
Chicago, Illinois, United States
Analysis of Human ALS Tissues and Registry of ALS Patients · TrialPath